BC Innovations | Apr 6, 2017
Translation in Brief

Humabodies come of age

With its transgenic mouse platform now in place, a deal with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) in hand and a new CSO announced this week, Crescendo Biologics Ltd. has pivoted from technology optimization to therapeutic...
BC Extra | Apr 15, 2016
Company News

CV/NASH play Madrigal finds public path via Synta merger

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) and Madrigal Pharmaceuticals Inc. (Fort Washington, Pa.) will reverse-merge to create a company focused on non-alcoholic steatohepatitis (NASH), cardiovascular and metabolic diseases. The combined, publicly traded company will retain Madrigal's name....
BC Extra | Oct 22, 2015
Clinical News

Synta halting ganetespib study after futility analysis

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) sank $1.30 (64%) to $0.74 after it said it will terminate the Phase III GALAXY-2 trial of ganetespib ( STA-9090 ) to treat advanced non-small cell lung cancer (NSCLC). Synta said that after...
BC Week In Review | Mar 10, 2014
Clinical News

Synta preclinical data

In mouse xenograft models of triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), 50 mg/kg STA-9183 safely delivered docetaxel at up to 7 times greater unconjugated docetaxel. Specifically, 50 mg/kg STA-9183 safely delivered...
BC Week In Review | Mar 10, 2014
Clinical News

Synta preclinical data

In mouse xenograft tumor models, STA-12-8666 safely delivered >10 times greater levels of SN-38, the active metabolite of irinotecan, vs. the maximum tolerated dose (MTD) of unconjugated irinotecan. Compared to the MTD of 50 mg/kg...
BC Innovations | Jan 30, 2014
Translation in Brief

Translational tidbits

Amgen's IBD gene hunt Amgen Inc. is teaming up with researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard to find new targets in inflammatory bowel disease. The partners hope an...
BC Week In Review | Sep 16, 2013
Company News

Synta cancer news

Synta launched its Hsp90-inhibitor drug conjugate (HDC) platform for cancer therapies. HDCs consist of an inhibitor of heat shock protein 90 (Hsp90) joined to a payload via a cleavable chemical linker, which the company said...
BioCentury | Sep 16, 2013
Tools & Techniques

Conjugation for concentration

Synta Pharmaceuticals Corp. 's Hsp90 inhibitor-drug conjugates may improve the therapeutic index of small molecule cancer agents by making them accumulate selectively in cancer cells. Synta thinks its products, dubbed HDCs, will reach higher concentrations...
BioCentury | Oct 31, 2011

Lessons from PSA debate

While the medical community debates a U.S. task force's recommendation against PSA screening for prostate cancer, the implications are far broader: The task force's methodology for subjectively balancing benefit and harm is being applied to...
BC Week In Review | Dec 8, 2008
Clinical News

BF-Derm1: Completed Phase II enrollment

Biofrontera completed enrollment of 51 patients in the placebo-controlled portion of a German and Russian Phase II trial evaluating BF-Derm1 for 8 weeks. Biofrontera AG (Xetra:B8F), Leverkusen, Germany   Product: BF-Derm1   Business: Dermatology  ...
Items per page:
1 - 10 of 21